J&J names Thibaut Mongon, existing customer wellness leader, as chief executive officer of brand-new spin-off business


Signs is presented beyond Johnson & & Johnson head office in New Brunswick, New Jacket, Aug. 1, 2020.

Mark Kauzlarich|Bloomberg|Getty Photos

Johnson & & Johnson(* )on Wednesday introduced that the existing head and also the primary monetary police officer of its customer wellness profile will certainly lead business when it dilates right into a different openly traded business in 2023. Thibaut Mongon, the existing leader of the customer wellness organization, will certainly end up being chief executive officer of the standalone business, and also Paul Ruh will certainly stay in his existing function of primary monetary police officer. Mongon has actually worked as J&J’s customer wellness leader given that 2019, and also Ruh has actually worked as CFO given that 2017.

Exec Chair Alex Gorsky claimed J&J carried out an exterior exec search, yet chose that Mongon and also Ruh were ideal furnished to lead the standalone business.

J&J introduced in November that it would certainly sheer off the customer wellness organization from its faster-growing clinical gadgets and also pharmaceutical profiles.

The customer wellness organization makes typical home items and also over the counter medications such as Tylenol, Band-Aid, Listerine, Neutrogena and also Aveena skin treatment, and also Johnson’s child items.

Customer wellness sales expanded 4.1% to $14.6 billion in 2021, while J&J’s pharmaceutical sales expanded 14.3% to $52 billion and also clinical gadgets sales expanded virtually 18% to $27 billion in 2014.

In the initial quarter of this year, customer wellness sales decreased 1.5% to $3.59 billion as compared to the exact same duration in 2021, because of provide restrictions on active ingredients and also product packaging products specifically for its skin wellness and also elegance items. Nevertheless, J&J CFO Joe Wolk claimed need was solid for over the counter medication such as Tylenol and also Motrin.

The customer wellness organization dealt with 10s of hundreds of suits in the last few years that affirmed its talc talcum powder included cancer-causing asbestos. J&J developed a subsidiary that was positioned in insolvency to fix the insurance claims. The business quit offering the talcum powder in the North American market in 2020, yet still offers its somewhere else on the planet.

CNBC Wellness & & Scientific Research

Review CNBC’s most recent international insurance coverage of the Covid pandemic:

Resource web link



.